RxDoctor Payments Data

Christopher Cosgrove, MD

Internal Medicine · Wilmington, NCNPI 1790717296

Payments from drug & device makers

$1,022in general payments, 2019–2025

Across 63 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$183
  • GSK$107
  • Abbott$83
  • Amgen$74
  • Pfizer$65
  • Biohaven Pharmaceutical Holding Company Ltd.$57
  • plus $453 from 20 others

What the payments were for

  • Food & beverage$1,01199%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,022 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$302,284
Medicare patients
798
Services billed
3,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban123$110,111
OzempicSemaglutide101$98,492
XareltoRivaroxaban38$48,544
JanuviaSitagliptin Phosphate55$40,920
JardianceEmpagliflozin43$26,116
WegovySemaglutide17$23,723
JanumetSitagliptin Phos/Metformin Hcl19$23,593
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$19,019
Breo ElliptaFluticasone/Vilanterol17$13,568
Repatha SureclickEvolocumab18$11,176
TrulicityDulaglutide12$11,009
FarxigaDapagliflozin Propanediol13$9,603
Enoxaparin Sodium14$8,528
Atorvastatin Calcium857$8,326
Pantoprazole Sodium509$8,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$183$122,215118 claims
PfizerEliquis, Lyrica, Paxlovid$65$119,942206 claims
Johnson & JohnsonXarelto$41$48,54438 claims
GSKTrelegy Ellipta, Breo Ellipta$107$32,58741 claims
Lilly USA, LLCTrulicity$25$11,00912 claims
AbbVieRestasis, Synthroid$29$10,07963 claims
AstraZenecaFarxiga$18$9,60313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →